Clinical Trials Logo
  1. Home
  2. Cystoid Macular Edema
  3. NCT00508040

Evaluation of Birdshot Retine Choroidopathy Treatment by Either Steroid or Interferon alpha2a — BIRDFERON  

Cystoid Macular Edema Clinical Trial

Official title:
Evaluation of Birdshot RETINE CHOROIDOPATHY Treatment by Either Steroid or Interferon alpha2a

Clinical Trial Summary

Birdshot Retine choroidopathy (BRC) is a sight threatening posterior uveitis. The long term visual outcome has recently be studied showing a legal blindness to 14% at 5 years. Visual acuity is threatened by macular edema (80%), macular atrophy, and choroidal neovascularization.

Clinical Trial Description

Birdshot Retine choroidopathy (BRC) is a sight threatening posterior uveitis. The long term visual outcome has recently be studied showing a legal blindness to 14% at 5 years. Visual acuity is threatened by macular edema (80%), macular atrophy, and choroidal neovascularization.

The conventional therapy includes in first line steroid therapy of which side effects are well known. If the daily steroid dose necessary to control the intra ocular inflammation is superior to 0.3 mg/kg/d a combined therapy to immunosuppressive drug is suggested in order to do a steroid sparing effect. Immunosuppressive drugs include increased infectious risks, hematologic and sterility troubles, and secondary malignancies. Moreover immunosuppressive drugs have a own toxic effect and The classical immunosuppressive drug used in BRC the cyclosporineA has a high level of nephrotoxicity.

That is the reason why immunomodulatory drugs as interferons have been suggested in BRC.

Interferon alpha2 a has been shown efficient in uveitis in Behcet's disease. We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not make the disease worse because of the slow pathologic processus. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00508040
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Completed
Phase Phase 2
Start date September 2007
Completion date January 2013
View Details
See also
  Status Clinical Trial Phase
Terminated NCT00114062 - Study to Treat Uveitis Associated Macular Edema Phase 2
Completed NCT03025945 - Prospective Study With Adjunctive Once Daily Topical Nepafenac 0.3% Versus Placebo N/A
Completed NCT01978015 - Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG Phase 4
Recruiting NCT05158699 - Effectiveness of Periocular Drug Injection in CATaract Surgery Phase 3
Withdrawn NCT02598869 - Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema Phase 4
Terminated NCT04527523 - Descemet Membrane Endothelial Keratoplasty vs. Descemet's Stripping With Endothelial Keratoplasty vs. Descemet Stripping Only
Completed NCT02294656 - Acute Pseudophakic Cystoid Macular Edema Treatment Trial: Intravitreal Ranibizumab Versus Triamcinolone Acetonide Phase 1
Withdrawn NCT00406172 - Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME) Phase 3
Not yet recruiting NCT04856670 - Assessing Diabetes Mellitus on Cytokine Analysis and Macular Edema Following FLACS
Completed NCT02609165 - Nerve Growth Factor Eye Drops Treatment in Patients With Retinitis Pigmentosa and Cystoid Macular Edema Phase 2
Withdrawn NCT00438243 - Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema. Phase 2
Completed NCT00464581 - Lucentis for Treatment of Macular Edema N/A
Active, not recruiting NCT03465124 - Evaluation of Central Macular Thickness in Femtosecond Laser-assisted Cataract Surgery N/A
Recruiting NCT02486484 - Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection Phase 2
Completed NCT00790803 - Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema N/A
Recruiting NCT04225611 - Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema Phase 1/Phase 2
Completed NCT05832996 - Cool vs Room-temperature Artificial Tears Phase 4
Completed NCT05615805 - The Effect of Ocular Rinse Volume on Surface Irritation After Intravitreal Injections N/A
Completed NCT00494494 - Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery Phase 4
Terminated NCT00346983 - Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics Phase 1/Phase 2